Publications en collaboration avec des chercheurs de Universidad de Valladolid (11)

2023

  1. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

2022

  1. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  2. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  2. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  3. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  4. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18

2020

  1. Clinical perspective and translational oncology of liquid biopsy

    Diagnostics, Vol. 10, Núm. 7

  2. Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers

    Diagnostics, Vol. 10, Núm. 4

2013

  1. Incidence of -93 MLH1 promoter polymorphism in familial and sporadic colorectal cancer

    Colorectal Disease, Vol. 15, Núm. 3

2003

  1. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects

    Human Mutation, Vol. 22, Núm. 4, pp. 301-312